Ameriprise Financial Inc. raised its stake in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 64.4% during the third quarter, HoldingsChannel reports. The firm owned 49,269 shares of the company’s stock after purchasing an additional 19,300 shares during the quarter. Ameriprise Financial Inc.’s holdings in Dova Pharmaceuticals were worth $1,196,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the business. Laurion Capital Management LP acquired a new stake in Dova Pharmaceuticals in the 2nd quarter valued at about $223,000. Bank of New York Mellon Corp acquired a new stake in Dova Pharmaceuticals in the 3rd quarter valued at about $340,000. JPMorgan Chase & Co. acquired a new stake in Dova Pharmaceuticals in the 2nd quarter valued at about $382,000. Vanguard Group Inc. acquired a new stake in Dova Pharmaceuticals in the 2nd quarter valued at about $390,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Dova Pharmaceuticals in the 2nd quarter valued at about $493,000. 26.20% of the stock is currently owned by institutional investors.
Shares of Dova Pharmaceuticals Inc (NASDAQ DOVA) opened at $30.05 on Thursday. Dova Pharmaceuticals Inc has a 12-month low of $16.98 and a 12-month high of $32.75. The firm has a market capitalization of $770.86 and a PE ratio of -33.76.
A number of equities research analysts have issued reports on the company. Jefferies Group increased their price target on Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research report on Tuesday, November 28th. Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research report on Wednesday, October 11th. BidaskClub lowered Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Finally, Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price target on the stock in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Dova Pharmaceuticals has an average rating of “Hold” and an average target price of $32.75.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
What are top analysts saying about Dova Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dova Pharmaceuticals and related companies.